Intriguingly, EGFRvIII is cross-activated by MET in GBM models [11] and MET inhibitors synergize with EGFR inhibitors against GBM xenografts harboring both EGFRvIII mutation and PTEN deletion [12]. Here, EGFR is linked to glioblastoma.